# MOTIV BTK Randomized Controlled Trial

Study · id `cardio:ct-nct05406622` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05406622](<https://clinicaltrials.gov/study/NCT05406622>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05406622

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 292 participants.

## Technical summary

Registry record NCT05406622. Randomized; single masking; primary purpose treatment. Start 2022-06-10 (actual); primary completion 2026-04-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 292 participants (planned count; ClinicalTrials.gov record NCT05406622, source copy `cardio:ctgov-nct05406622-2026-06-18`, retrieved 2026-10-31)
- Started: 2022-06-10 (actual) (ClinicalTrials.gov record NCT05406622, source copy `cardio:ctgov-nct05406622-2026-06-18`, retrieved 2026-10-31)
- Primary completion: 2026-04-30 (actual) (ClinicalTrials.gov record NCT05406622, source copy `cardio:ctgov-nct05406622-2026-06-18`, retrieved 2026-10-31)
- Completion: 2030-03-31 (anticipated) (ClinicalTrials.gov record NCT05406622, source copy `cardio:ctgov-nct05406622-2026-06-18`, retrieved 2026-10-31)
- Countries: United States; Germany (ClinicalTrials.gov record NCT05406622, source copy `cardio:ctgov-nct05406622-2026-06-18`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05406622-2026-06-18`, retrieved 2026-10-31)

## The registry's words

- Brief title: MOTIV BTK Randomized Controlled Trial
- Condition: Critical Limb Ischemia
- Intervention (Device): MOTIV Sirolimus-Eluting Bioresorbable Scaffold
- Intervention (Device): Percutaneous Transluminal Angioplasty (PTA) Device
- Lead sponsor: REVA Medical, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry lists this organization as the lead sponsor: REVA Medical, Inc. (`cardio:org-reva-medical-inc`)

## Provenance

Content hash: b5aa06436d2177e00a99cb3ade3de2dc7b72cf838984d81b86ac6d4fcdfbaad8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
